Leqvio FDA Approval

Expect modest initial ramp as we lay the foundation for multi-blockbuster potential H1 2022-laying foundation ■ High interest from early adopters ■ Independent HCPs ready for buy-and-bill ■ AICs responding to demand " " Temporary J-code Coverage to label for FFS Medicare H2 2022 - getting to scale ■ Permanent J-code available ■ ☐ Buy-and-bill capabilities established System P&T committee review complete ■ Finalization of commercial & Medicare Advantage payer coverage policies Lead indicators # of health systems/ facilities adopting LeqvioⓇ # of systems with repeat orders # of AIC facilities administering LeqvioⓇ Intent to prescribe HCP Healthcare Professional AIC - Alternative Injection Center P&T Pharmacy and Therapeutics FFS-Fee For Service 25 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation NOVARTIS | Reimagining Medicine

View entire presentation